Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Czechia / NCT04427163
Recruiting Observational

Assesment of Multiomics Profiles in Health and Disease.

NCT04427163 · tracked via the Priya Life Science Czechia tracker
Sponsor
The Institute of Molecular and Translational Medicine, Czech Republic
Phase
Observational
Started
2018-09-01
Last updated
2026-02-13

Condition(s) studied

Genetic Predisposition to Disease

Investigational drug(s) / intervention(s)

Blood sample analysisHealth statusRace and ethnicity

Blood sample analysis: Nucleic acids sequencing, presence of proteins and metabolites.

Health status: Health status will be examined by a physician and subject will complete a health status questionnaire.

Race and ethnicity: Subject will complete race and ethnicity questionnaire to make sure subjects are from the Czech population.

Study summary

This study will determine reference genomic, transcriptomic, proteomic and metabolomic profiles in Czech population and will evaluate its correlation with the disease phenotype.

Eligibility

Sex
ALL
Min age
18 Years
Max age
68 Years
Healthy volunteers
Accepted
Inclusion Criteria: * age 18 - 68 years * (for the first 1100 subjects): * healthy volunteers without genetically dependent disease and without such a disease in a family * healthy volunteer without the preliminary evidence of civilizational diseases such as hypertension, diabetes, autoimmune and tumor diseases or acute infectional diseases; clinically manifesting cardiovascular or pulmonary disability. * subject without permanent of long-term medication in the time of biological sampling. Exclusion Criteria: * not complying with inclusion criteria

Primary outcome measure(s)

  • Whole Genome (Exom) Sequencing of the Healthy Volunteers - establishment of the HEALTHY VOLUNTEER REFERENCE GENOME (min. 1000 individuals) — 72 months
    Establishment of the Healthy Volunteers Whole Genome (Exom) Reference Database typical for the population of the Czech Republic/Central Europe.
  • Whole Genome (Exom) Sequencing of the patient groups with different diseases and their comparison to the HEALTHY VOLUNTEER REFERENCE GENOME — 72 months
    Whole Genome (Exom) Sequencing of the patient populations presenting various diseases. Based on the comparison with the HEALTHY VOLUNTEER REFERENCE GENOME - determination of various genetic polymorphisms (single nucleotide polymorphisms, insertions, deletions, inversions, copy-number variations etc.) and giving these into correlation with disease phenotypes.

Trial sites (1)

FacilityCityRegionStatus
University Hospital Olomouc Olomouc Czechia Recruiting

More The Institute of Molecular and Translational Medicine, Czech Republic trials in Czechia

The Effect of Multimodal Treatment of Rectal Cancer on Circulating Tumor Cells: A Prospective, Observational Study Recruiting
Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients Recruiting
Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening. Recruiting
Biomarkers of Endometrial Receptivity Recruiting
Self-sampling for Non-attenders to Cervical Cancer Screening Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04427163 on ClinicalTrials.gov ↗ ← All trials in Czechia